Theranexus (EPA:ALTHX) | Finanzwire

Basculer en Français

9473	Companies
185423	Keywords
117773	Articles
99292	Press releases

Home
Companies
Theranexus

BRIEF

published on 07/17/2025 at 18:05, 4 months 18 days ago

Half-Yearly Review of the Theranexus Liquidity Contract

Liquidity Contract PORTZAMPARC Financial Statement Biopharmaceuticals Theranexus
BRIEF

published on 07/10/2025 at 18:05, 4 months 25 days ago

Theranexus Reveals its Cash Position as of June 30, 2025

Treasury Biopharmaceutical Innovation Theranexus Batten-1 Neurological Diseases
PRESS RELEASE

published on 07/10/2025 at 18:00, 4 months 25 days ago

THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 JUNE 2025
Theranexus, a biopharmaceutical company, reports a cash position of €2.1M as of 30 June 2025, with upcoming funds and financial visibility through Q2 2026. CEO discusses collaborations and strategic progress. H1 2025 results expected on September 25, 2025

Cash Position Biopharmaceutical Financial Publication Theranexus Rare Neurological Diseases
BRIEF

published on 05/13/2025 at 18:05, 6 months 22 days ago

Theranexus and BBDF reveal promising results for Batten-1

Theranexus Batten-1 BBDF Batten Disease Visual Acuity
PRESS RELEASE

published on 05/13/2025 at 18:00, 6 months 22 days ago

THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION ANNOUNCE STRONG POSITIVE REAL-WORLD DATA SUPPORTING BATTEN-1 EFFICACY FOR THE TREATMENT OF BATTEN DISEASE
Theranexus and BBDF announce new data supporting Batten-1 (miglustat) efficacy for CLN3 disease treatment. Results show significant preservation of visual acuity in treated patients over 12 months. Real-world analysis aligns with Phase 3 trial design

Theranexus Batten-1 BBDF Visual Acuity CLN3 Disease
BRIEF

published on 04/29/2025 at 19:05, 7 months 5 days ago

Theranexus: 2024 Annual Review and New Perspectives

Financial Results Partnerships Theranexus Batten-1 Grants
PRESS RELEASE

published on 04/29/2025 at 19:00, 7 months 5 days ago

THERANEXUS PUBLISHES ITS 2024 FULL-YEAR RESULTS, PRESENTS ITS PROGRESS REPORT AND CLOSES ITS EQUITY LINE
Theranexus publishes financial results for 2024 & cash position as of March 31, 2025, presents progress report & plans for Batten-1 drug candidate. Board approves accounts. Continues strategic partnerships & developments

Financial Results Strategic Partnerships Clinical Trials Theranexus Batten-1
BRIEF

published on 03/06/2025 at 18:05, 8 months 29 days ago

Modification of the Theranexus liquidity contract

Liquidity Contract AMF PORTZAMPARC Theranexus Rare Neurological Diseases
BRIEF

published on 01/31/2025 at 18:10, 10 months 4 days ago

Half-yearly report on Theranexus' liquidity contract with Portzamparc

Liquidity Contract Transactions PORTZAMPARC Half-yearly Report Theranexus
BRIEF

published on 01/30/2025 at 18:05, 10 months 5 days ago

Theranexus Strengthens its Treasury and Develops its Partnerships

Treasury Theranexus Neurological Diseases Exeltis Partnership Bpifrance Financing

Accesswire

Published on 12/05/2025 at 02:35, 7 hours 39 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 7 hours 44 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 9 hours 14 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 11 hours 9 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 11 hours 14 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 09:40, 34 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 44 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 1 hour 9 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 1 hour 13 minutes ago

Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 09:00, 1 hour 14 minutes ago

SPECTRIS PLC - Removal

Les Echos

Published on 12/05/2025 at 08:45, 1 hour 29 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 16 hours 14 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 16 hours 29 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 16 hours 30 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 3 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE